22159 – Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301)
22101 – Ph3 Imlun vs Endo ER+ HER2- BC
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)
20210
Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)
17079
MammaPrint, Blueprint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
18263
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
21239
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)
21270
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ZN-c3-005| GOG 3066)
20186 – Ph2 Tumor-Agnostic Precision TAPISTRY
TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU (TAPISTRY) PHASE II PLATFORM TRIAL (BO41932)
21236-ALL DISEASE: DETECT REGISTRY
Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing ¨C Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
HNSCC – OPEN
Kidney/Renal – OPEN
Liver – OPEN
Bladder – OPEN
Uterine – OPEN
Stomach – OPEN
Cervical – OPEN
Ovarian – OPEN
Vulva – OPEN
Small Intestine – OPEN
Thyroid – OPEN
Testis – OPEN
***Ovarian and Bladder cancer subjects can be enrolled under suspicion of cancer***